Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Goldman Sachs analyst Andrea Newkirk reinstates Arrowhead Pharma (NASDAQ:ARWR) with a Neutral and announces $74 price target.
Goldman Sachs analyst Andrea Newkirk reinstates Arrowhead Pharma (NASDAQ:ARWR) with a Neutral and announces $74 price target.